Literature DB >> 11770903

Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology.

Christine E Fuller1, Arie Perry.   

Abstract

Over the last decade, fluorescence in situ hybridization (FISH) has emerged as a powerful clinical and research tool for the assessment of target DNA dosages within interphase nuclei. Detectable alterations include aneusomies, deletions, gene amplifications, and translocations, with primary advantages to the pathologist including its basis in morphology, its applicability to archival, formalin-fixed paraffin-embedded (FFPE) material, and its similarities to immunohistochemistry. Recent technical advances such as improved hybridization protocols, markedly expanded probe availability resulting from the human genome sequencing initiative, and the advent of high-throughput assays such as gene chip and tissue microarrays have greatly enhanced the applicability of FISH. In our lab, we currently utilize only a limited battery of DNA probes for routine diagnostic purposes, with determination of chromosome 1p and 19q dosage in oligodendroglial neoplasms representing the most common application. However, research applications are numerous and will likely translate into a growing list of clinically useful markers in the near future. In this review, we highlight the advantages and disadvantages of FISH and familiarize the reader with current applications in diagnostic and investigative neuropathology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11770903     DOI: 10.1111/j.1750-3639.2002.tb00424.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  15 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

Review 2.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

Review 3.  Neuropathology for the neuroradiologist: fluorescence in situ hybridization.

Authors:  F J Wippold; A Perry
Journal:  AJNR Am J Neuroradiol       Date:  2007-03       Impact factor: 3.825

4.  Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.

Authors:  Daniel Antunes Moreno; Luciane Sussuchi da Silva; Maicon Fernando Zanon; Murilo Bonatelli; Flávia Escremim de Paula; Marcus de Medeiros Matsushita; Gustavo Ramos Teixeira; Iara Viana Vidigal Santana; Fabiano Saggioro; Luciano Neder; João N Stavale; Suzana Maria Fleury Malheiros; Matheus Lima; Glaucia Noeli Maroso Hajj; Hernan Garcia-Rivello; Silvia Christiansen; Susana Nunes; Maria João Gil da Costa; Maria José Soares; Jorge Pinheiro; Carlos Almeida Junior; Bruna Minniti Mançano; Rui Manuel Reis
Journal:  J Neurooncol       Date:  2022-02-15       Impact factor: 4.130

5.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

6.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.

Authors:  Daniel J Brat; Wendy F Seiferheld; Arie Perry; Elizabeth H Hammond; Kevin J Murray; Alan R Schulsinger; Minesh P Mehta; Walter J Curran
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

7.  Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.

Authors:  Xiaohui Ren; Haihui Jiang; Xiangli Cui; Yong Cui; Jun Ma; Zhongli Jiang; Dali Sui; Song Lin
Journal:  Neuro Oncol       Date:  2013-07-16       Impact factor: 12.300

8.  Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.

Authors:  Gabriel A Bien-Willner; Dolores López-Terrada; Meena B Bhattacharjee; Kayuri U Patel; Pawel Stankiewicz; James R Lupski; John D Pfeifer; Arie Perry
Journal:  Neuro Oncol       Date:  2012-05-09       Impact factor: 12.300

9.  A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.

Authors:  Sandra Camelo-Piragua; Michael Jansen; Aniruddha Ganguly; James ChulMin Kim; Arjola K Cosper; Dora Dias-Santagata; Catherine L Nutt; A John Iafrate; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2011-02       Impact factor: 3.148

10.  Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.

Authors:  Céline Duval; Marie de Tayrac; Karine Michaud; Florian Cabillic; Claudie Paquet; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.